Intrexon Corp (XON) 50.16 $XON
Intrexon (XON) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 06, 6:07AM CST
Intrexon (XON) Shares March Higher, Can It Continue?
XON: 50.16 (+0.66)
Can Intrexon Corp's Jaw-Dropping Growth Continue after Tuesday's 20% Jump?
Maxx Chatsko, The Motley Fool - Motley Fool - Thu Mar 05, 8:12AM CST
Image source: John Goode/ Flickr . Who said fame only lasts for 15 minutes? Already on a tear entering 2015, synthetic biology leader Intrexon roared higher after reporting full-year 2014 earnings earlier this week. A little over two months...
ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66)
Why Intrexon Corp Catapulted Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 03, 3:10PM CST
Source: Intrexon Corporation Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Intrexon...
ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66)
Intrexon ups revenues 338% in Q4
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 9:27AM CST
XON: 50.16 (+0.66)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:16AM CST
MDR: 3.32 (-0.05), ONCY: 0.90 (-0.15), PLUG: 2.97 (+0.01), OCN: 8.91 (+0.24), XON: 50.16 (+0.66), TEDU: 10.24 (+0.21), BIOC: 3.10 (-0.26), LL: 33.32 (-0.51), MNKD: 5.47 (-0.26), CYCC: 1.05 (-0.01), CYTX: 1.11 (-0.05), DATE: 5.06 (-0.04), TSEM: 17.50 (-0.31), LEAF: 48.59 (-1.19), FNJN: 2.42 (-0.10), AMCO: 1.28 (-0.02)
Soligenix Announces Positive Recommendation by Data Review Committee on its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
PR Newswire - Tue Mar 03, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has received a positive recommendation from the Data Review Committee (DRC) to continue enrolling into the company's Phase 2 study evaluating SGX942, a first-in-class innate defense regulator (IDR), as a treatment for oral mucositis in patients undergoing chemoradiation (CRT) therapy for head and neck cancer. Following DRC review of available data on the subjects enrolled in the trial, the committee recommended that enrollment include an additional 20 subjects randomized into either a single SGX942 dose group or the placebo group to allow for a more targeted assessment of the drug's potential effect and to inform final dose selection in this patient population.
XON: 50.16 (+0.66)
Synthetic Biologics to Present at the 27th Annual ROTH Conference
PR Newswire - Tue Mar 03, 5:57AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that Jeffrey Riley, Chief Executive Officer, is scheduled to present at the 27th Annual ROTH Conference being held on March 8-11, 2015 at the Ritz-Carlton, Laguna Niguel in Dana Point, CA. Mr. Riley is scheduled to present on Tuesday, March 10, 2015 at 1:00 p.m. (Pacific Time).
SYN: 2.45 (+0.10), XON: 50.16 (+0.66)
Intrexon's (XON) CEO R.J. Kirk on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 02, 8:38PM CST
XON: 50.16 (+0.66)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 4:37PM CST
GWRE: 52.98 (-0.06), MDR: 3.32 (-0.05), ST: 55.99 (-0.99), GRUB: 42.32 (-0.87), ISDR: 9.35 (-0.65), EWQ: 25.81 (-0.51), XON: 50.16 (+0.66), OPWR: 9.89 (-0.53), NSAM: 24.48 (-0.27), NE: 15.19 (-0.78)
Intrexon (XON) Stock Climbs in After-Hours Trading Today Following Earnings Release
at The Street - Mon Mar 02, 3:30PM CST
Intrexon (XON) shares are rising in after-hours trading after beating analysts' fourth quarter earnings and revenue expectations.
XON: 50.16 (+0.66)
Intrexon beats by $0.10, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 3:12PM CST
XON: 50.16 (+0.66)
Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results
PR Newswire - Mon Mar 02, 3:05PM CST
Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced its fourth quarter and full year results for 2014.
XON: 50.16 (+0.66)
Synthetic Biologics Announces Two Poster Presentations of Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at ECCMID 2015
PR Newswire - Mon Mar 02, 5:57AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that preclinical results supporting the development of SYN-005 for the treatment of Pertussis will be highlighted at ECCMID 2015 (European Congress of Clinical Microbiology and Infectious Diseases), April 25-28, in Copenhagen, Denmark. Two posters will be presented under the Respiratory Infections category all four days at ECCMID on 50 ePoster stations, as follows:
SYN: 2.45 (+0.10), XON: 50.16 (+0.66)
Intrexon to buy Okanagan Specialty Fruits in the first half of 2015
M2 - Mon Mar 02, 4:11AM CST
Synthetic biology company Intrexon (NYSE:XON) Friday reported an agreement to acquire Okanagan Specialty Fruits (OSF) for USD31m in Intrexon common stock plus USD10m in upfront cash.
XON: 50.16 (+0.66)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Mar 01, 4:35PM CST
MBI: 9.25 (-0.12), GWRE: 52.98 (-0.06), CODI: 16.42 (-0.10), MDR: 3.32 (-0.05), HTGC: 14.60 (+0.04), NBR: 12.69 (-0.44), NTRI: 18.37 (-0.51), XON: 50.16 (+0.66), STKL: 9.88 (+0.05), OPWR: 9.89 (-0.53), CZR: 9.63 (-0.53), PANW: 140.73 (-2.41), INN: 13.45 (-0.35), CMLS: 3.02 (-0.01), MTDR: 21.23 (-1.39), ARNA: 4.32 (+0.09), MCEP: 6.09 (-0.17), SLXP: 158.01 (+0.57), BALT: 1.52 (-0.04), MYL: 55.44 (-1.25), SN: 13.47 (-0.42), EPIQ: 17.04 (-0.47), CHUY: 22.48 (-0.64), DTSI: 32.74 (-0.89), PRAA: 49.58 (-0.39), HALO: 15.20 (-0.19), CIM: 3.13 (-0.06), CKEC: 30.28 (-0.13)
This Billionaire CEO Just Made Another Biotech Acquisition -- and Hardly Anyone Noticed
Maxx Chatsko, The Motley Fool - Motley Fool - Sat Feb 28, 1:08PM CST
Investors have rushed to acquire shares of synthetic biology company Intrexon in the first two months of 2015. Most of the enthusiasm stems from a recent partnership with the University of Texas MD Anderson Cancer Center and Ziopharm to...
ZIOP: 13.38 (-0.43), MRK: 56.84 (-1.14), XON: 50.16 (+0.66)
Intrexon: Back-End Economics Could Generate Huge Upside
Chris Bunge - Seeking Alpha - Fri Feb 27, 11:20AM CST
"I think the biggest innovations of the 21st century will be at the intersection of biology and technology. A new era is beginning." --Steve Jobs As an investor important characteristics of a company lie in the product or service they...
ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66)
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 32.97 (-0.74), CASM: 1.35 (-0.02), AMRN: 1.78 (+0.11), XON: 50.16 (+0.66), OSIR: 18.40 (+1.46), CPIX: 6.95 (+0.20), AMED: 27.62 (-0.73), CTIC: 2.65 (-0.07), INSY: 57.69 (+0.08), ECYT: 6.21 (-0.04), CMRX: 39.33 (-1.46), KYTH: 53.13 (+3.13), TRIB: 18.74 (+0.22), GALE: 1.88 (-0.12), ARNA: 4.32 (+0.09), XLRN: 40.55 (-0.79), ACRX: 8.74 (-0.27), ENDP: 87.03 (-0.68), DPLO: 28.94 (-1.54), SLXP: 158.01 (+0.57), PPHM: 1.63 (+0.06), MYL: 55.44 (-1.25), CBPO: 82.88 (+1.08), RGEN: 25.07 (-0.71), HALO: 15.20 (-0.19), ALIM: 5.11 (+0.21), ACHN: 11.39 (+0.40), GERN: 3.50 (-0.28), DARA: 0.80 (-0.02), SCMP: 15.64 (+0.49), ICPT: 266.14 (+4.96), CDXS: 3.70 (-0.29), PCRX: 96.63 (-1.77), PBYI: 232.83 (-10.34), FOLD: 8.49 (-0.16)
Expert Briefing on Biotech Stocks - Lexicon Pharma, Sunesis Pharma, Navidea Biopharma, Tekmira Pharma, and Intrexon
PR Newswire - Thu Feb 19, 7:35AM CST
Editor Note: For more information about this release, please scroll to bottom.
NAVB: 1.67 (-0.03), LXRX: 1.17 (+0.05), XON: 50.16 (+0.66), TKMR: 18.76 (-0.93), SNSS: 2.26 (-0.03)
Don't Mimic Warren Buffett - Cramer's Mad Money (2/18/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Feb 19, 6:35AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, February 18. Cramer started the show by mentioning that piggybacking or mimicking someone's strategy of buying stocks is a bad idea. The market moved on...
WFM: 55.66 (-0.49), NKE: 96.91 (-1.55), GMCR: 126.24 (-2.81), SLXP: 158.01 (+0.57), XON: 50.16 (+0.66), WWAV: 41.79 (-0.63), SBUX: 92.21 (-1.42), UA: 74.80 (-0.99), VDSI: 22.58 (-0.73), IBM: 158.50 (-2.68), DE: 90.26 (-0.20), SIX: 45.97 (-0.79), KKD: 21.01 (-0.64), BRK.B: 145.28 (-0.78), BRK.A: 218,811.00 (-689.00), FTNT: 33.60 (-0.64), HTA: 25.77 (-1.53)
Intrexon (XON) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 06, 6:07AM CST
Intrexon (XON) Shares March Higher, Can It Continue?
XON: 50.16 (+0.66)
Can Intrexon Corp's Jaw-Dropping Growth Continue after Tuesday's 20% Jump?
Maxx Chatsko, The Motley Fool - Motley Fool - Thu Mar 05, 8:12AM CST
Image source: John Goode/ Flickr . Who said fame only lasts for 15 minutes? Already on a tear entering 2015, synthetic biology leader Intrexon roared higher after reporting full-year 2014 earnings earlier this week. A little over two months...
ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66)
Why Intrexon Corp Catapulted Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 03, 3:10PM CST
Source: Intrexon Corporation Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Intrexon...
ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66)
Intrexon ups revenues 338% in Q4
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 9:27AM CST
XON: 50.16 (+0.66)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:16AM CST
MDR: 3.32 (-0.05), ONCY: 0.90 (-0.15), PLUG: 2.97 (+0.01), OCN: 8.91 (+0.24), XON: 50.16 (+0.66), TEDU: 10.24 (+0.21), BIOC: 3.10 (-0.26), LL: 33.32 (-0.51), MNKD: 5.47 (-0.26), CYCC: 1.05 (-0.01), CYTX: 1.11 (-0.05), DATE: 5.06 (-0.04), TSEM: 17.50 (-0.31), LEAF: 48.59 (-1.19), FNJN: 2.42 (-0.10), AMCO: 1.28 (-0.02)
Soligenix Announces Positive Recommendation by Data Review Committee on its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
PR Newswire - Tue Mar 03, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has received a positive recommendation from the Data Review Committee (DRC) to continue enrolling into the company's Phase 2 study evaluating SGX942, a first-in-class innate defense regulator (IDR), as a treatment for oral mucositis in patients undergoing chemoradiation (CRT) therapy for head and neck cancer. Following DRC review of available data on the subjects enrolled in the trial, the committee recommended that enrollment include an additional 20 subjects randomized into either a single SGX942 dose group or the placebo group to allow for a more targeted assessment of the drug's potential effect and to inform final dose selection in this patient population.
XON: 50.16 (+0.66)
Synthetic Biologics to Present at the 27th Annual ROTH Conference
PR Newswire - Tue Mar 03, 5:57AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that Jeffrey Riley, Chief Executive Officer, is scheduled to present at the 27th Annual ROTH Conference being held on March 8-11, 2015 at the Ritz-Carlton, Laguna Niguel in Dana Point, CA. Mr. Riley is scheduled to present on Tuesday, March 10, 2015 at 1:00 p.m. (Pacific Time).
SYN: 2.45 (+0.10), XON: 50.16 (+0.66)
Intrexon's (XON) CEO R.J. Kirk on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 02, 8:38PM CST
XON: 50.16 (+0.66)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 4:37PM CST
GWRE: 52.98 (-0.06), MDR: 3.32 (-0.05), ST: 55.99 (-0.99), GRUB: 42.32 (-0.87), ISDR: 9.35 (-0.65), EWQ: 25.81 (-0.51), XON: 50.16 (+0.66), OPWR: 9.89 (-0.53), NSAM: 24.48 (-0.27), NE: 15.19 (-0.78)
Intrexon (XON) Stock Climbs in After-Hours Trading Today Following Earnings Release
at The Street - Mon Mar 02, 3:30PM CST
Intrexon (XON) shares are rising in after-hours trading after beating analysts' fourth quarter earnings and revenue expectations.
XON: 50.16 (+0.66)
Intrexon beats by $0.10, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 3:12PM CST
XON: 50.16 (+0.66)
Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results
PR Newswire - Mon Mar 02, 3:05PM CST
Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced its fourth quarter and full year results for 2014.
XON: 50.16 (+0.66)
Synthetic Biologics Announces Two Poster Presentations of Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at ECCMID 2015
PR Newswire - Mon Mar 02, 5:57AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that preclinical results supporting the development of SYN-005 for the treatment of Pertussis will be highlighted at ECCMID 2015 (European Congress of Clinical Microbiology and Infectious Diseases), April 25-28, in Copenhagen, Denmark. Two posters will be presented under the Respiratory Infections category all four days at ECCMID on 50 ePoster stations, as follows:
SYN: 2.45 (+0.10), XON: 50.16 (+0.66)
Intrexon to buy Okanagan Specialty Fruits in the first half of 2015
M2 - Mon Mar 02, 4:11AM CST
Synthetic biology company Intrexon (NYSE:XON) Friday reported an agreement to acquire Okanagan Specialty Fruits (OSF) for USD31m in Intrexon common stock plus USD10m in upfront cash.
XON: 50.16 (+0.66)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Mar 01, 4:35PM CST
MBI: 9.25 (-0.12), GWRE: 52.98 (-0.06), CODI: 16.42 (-0.10), MDR: 3.32 (-0.05), HTGC: 14.60 (+0.04), NBR: 12.69 (-0.44), NTRI: 18.37 (-0.51), XON: 50.16 (+0.66), STKL: 9.88 (+0.05), OPWR: 9.89 (-0.53), CZR: 9.63 (-0.53), PANW: 140.73 (-2.41), INN: 13.45 (-0.35), CMLS: 3.02 (-0.01), MTDR: 21.23 (-1.39), ARNA: 4.32 (+0.09), MCEP: 6.09 (-0.17), SLXP: 158.01 (+0.57), BALT: 1.52 (-0.04), MYL: 55.44 (-1.25), SN: 13.47 (-0.42), EPIQ: 17.04 (-0.47), CHUY: 22.48 (-0.64), DTSI: 32.74 (-0.89), PRAA: 49.58 (-0.39), HALO: 15.20 (-0.19), CIM: 3.13 (-0.06), CKEC: 30.28 (-0.13)
This Billionaire CEO Just Made Another Biotech Acquisition -- and Hardly Anyone Noticed
Maxx Chatsko, The Motley Fool - Motley Fool - Sat Feb 28, 1:08PM CST
Investors have rushed to acquire shares of synthetic biology company Intrexon in the first two months of 2015. Most of the enthusiasm stems from a recent partnership with the University of Texas MD Anderson Cancer Center and Ziopharm to...
ZIOP: 13.38 (-0.43), MRK: 56.84 (-1.14), XON: 50.16 (+0.66)
Intrexon: Back-End Economics Could Generate Huge Upside
Chris Bunge - Seeking Alpha - Fri Feb 27, 11:20AM CST
"I think the biggest innovations of the 21st century will be at the intersection of biology and technology. A new era is beginning." --Steve Jobs As an investor important characteristics of a company lie in the product or service they...
ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66)
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 32.97 (-0.74), CASM: 1.35 (-0.02), AMRN: 1.78 (+0.11), XON: 50.16 (+0.66), OSIR: 18.40 (+1.46), CPIX: 6.95 (+0.20), AMED: 27.62 (-0.73), CTIC: 2.65 (-0.07), INSY: 57.69 (+0.08), ECYT: 6.21 (-0.04), CMRX: 39.33 (-1.46), KYTH: 53.13 (+3.13), TRIB: 18.74 (+0.22), GALE: 1.88 (-0.12), ARNA: 4.32 (+0.09), XLRN: 40.55 (-0.79), ACRX: 8.74 (-0.27), ENDP: 87.03 (-0.68), DPLO: 28.94 (-1.54), SLXP: 158.01 (+0.57), PPHM: 1.63 (+0.06), MYL: 55.44 (-1.25), CBPO: 82.88 (+1.08), RGEN: 25.07 (-0.71), HALO: 15.20 (-0.19), ALIM: 5.11 (+0.21), ACHN: 11.39 (+0.40), GERN: 3.50 (-0.28), DARA: 0.80 (-0.02), SCMP: 15.64 (+0.49), ICPT: 266.14 (+4.96), CDXS: 3.70 (-0.29), PCRX: 96.63 (-1.77), PBYI: 232.83 (-10.34), FOLD: 8.49 (-0.16)
Expert Briefing on Biotech Stocks - Lexicon Pharma, Sunesis Pharma, Navidea Biopharma, Tekmira Pharma, and Intrexon
PR Newswire - Thu Feb 19, 7:35AM CST
Editor Note: For more information about this release, please scroll to bottom.
NAVB: 1.67 (-0.03), LXRX: 1.17 (+0.05), XON: 50.16 (+0.66), TKMR: 18.76 (-0.93), SNSS: 2.26 (-0.03)
Don't Mimic Warren Buffett - Cramer's Mad Money (2/18/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Feb 19, 6:35AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, February 18. Cramer started the show by mentioning that piggybacking or mimicking someone's strategy of buying stocks is a bad idea. The market moved on...
WFM: 55.66 (-0.49), NKE: 96.91 (-1.55), GMCR: 126.24 (-2.81), SLXP: 158.01 (+0.57), XON: 50.16 (+0.66), WWAV: 41.79 (-0.63), SBUX: 92.21 (-1.42), UA: 74.80 (-0.99), VDSI: 22.58 (-0.73), IBM: 158.50 (-2.68), DE: 90.26 (-0.20), SIX: 45.97 (-0.79), KKD: 21.01 (-0.64), BRK.B: 145.28 (-0.78), BRK.A: 218,811.00 (-689.00), FTNT: 33.60 (-0.64), HTA: 25.77 (-1.53)
